These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 33968014)

  • 1. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.
    Etxebeste-Mitxeltorena M; Del Rincón-Loza I; Martín-Antonio B
    Front Immunol; 2021; 12():717850. PubMed ID: 34447383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
    Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future perspectives on engineered T cells for cancer.
    Posey AD; Young RM; June CH
    Trends Cancer; 2024 Aug; 10(8):687-695. PubMed ID: 38853073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
    Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
    Front Immunol; 2021; 12():714822. PubMed ID: 34367185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
    Lanitis E; Rota G; Kosti P; Ronet C; Spill A; Seijo B; Romero P; Dangaj D; Coukos G; Irving M
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33156338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
    Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
    Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in T-cell Immunotherapies.
    Stroncek DF; Reddy O; Highfill S; Panch SR
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):825-837. PubMed ID: 31466607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of adoptive T cell therapy in cancer.
    Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
    Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?
    Mojsilovic SS; Mojsilovic S; Villar VH; Santibanez JF
    Anal Cell Pathol (Amst); 2021; 2021():5523055. PubMed ID: 34476174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T cell therapy: points to consider.
    Yee C
    Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.